Ifeanyi Elibe Mba

Mr. Ifeanyi Elibe Mba

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2022 in Brazilian Journal of Microbiology
Verified
Journal Article
Closed access
PDF file
HSHyelnaya Cletus Sharndama
Hyelnaya Cletus Sharndama
IMIfeanyi Elibe Mba
Ifeanyi Elibe Mba

30 July 2022 in Microbiological Research
Verified
Journal Article
Closed access
NANgozi Joannes Anyaegbunam
Ngozi Joannes Anyaegbunam
CAChijioke Chinedu Anekpo
Chijioke Chinedu Anekpo
ZAZikora Kizito Glory Anyaegbunam
Zikora Kizito Glory Anyaegbunam
YDYandev Doowuese
Yandev Doowuese
CCChinwe Blessing Chinaka
Chinwe Blessing Chinaka
IMIfeanyi Elibe Mba
Ifeanyi Elibe Mba

22 March 2023 in Tropical Medicine & International Health
Verified
Journal Article
Closed access
IMIfeanyi Elibe Mba
Ifeanyi Elibe Mba
HSHyelnaya Cletus Sharndama
Hyelnaya Cletus Sharndama
ZAZikora Kizito Glory Anyaegbunam
Zikora Kizito Glory Anyaegbunam
CAChijioke Chinedu Anekpo
Chijioke Chinedu Anekpo
BABen Chibuzo Amadi
Ben Chibuzo Amadi
OOOnyekachi Philomena Okeke
Onyekachi Philomena Okeke

28 December 2023 in Biosafety and Health
Verified
Journal Article
Open access
ZAZikora Kizito Glory Anyaegbunam
Zikora Kizito Glory Anyaegbunam
IMIfeanyi Elibe Mba
Ifeanyi Elibe Mba
YDYandev Doowuese
Yandev Doowuese
NANgozi J. Anyaegbunam
Ngozi J. Anyaegbunam
TMToluwalase Mba
Toluwalase Mba
EEEmmanuel A. Eze
Emmanuel A. Eze
• Infections caused by drug-resistant pathogens pose a significant challenge threatening therapeutic efforts. • Non-medical drivers are significant sources and routes for resistant dissemination. • Overcoming antimicrobial resistance (AMR) requires a holistic approach involving different biomaterials, and vaccines are central to achieving this feat. • Heightened surveillance efforts could help to understand circulating bacterial clones of importance in African regions. • Integrating scalable genomics into routine surveillance programs are critical to mitigating AMR.

17 February 2024 in World Journal of Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
NANgozi J. Anyaegbunam
Ngozi J. Anyaegbunam
IMIfeanyi Elibe Mba
Ifeanyi Elibe Mba
AIAbimbola Olufunke Ige
Abimbola Olufunke Ige
TOTosin Emmanuel Ogunrinola
Tosin Emmanuel Ogunrinola
OEOkpe Kenneth Emenike
Okpe Kenneth Emenike
DODavid B. Olawade
David B. Olawade

27 April 2021 in Infectious Diseases
Verified
Journal Article
Closed access
IMIfeanyi Elibe Mba
Ifeanyi Elibe Mba
HSHyelnaya Cletus Sharndama
Hyelnaya Cletus Sharndama
GOGoodness Ogechi Osondu-Chuka
Goodness Ogechi Osondu-Chuka
OOOnyekachi Philomena Okeke
Onyekachi Philomena Okeke
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constitutes the most significant global public health challenge in a century. It has reignited research interest in coronavirus. While little information is available, research is currently in progress to comprehensively understand the general biology and immune response mechanism against SARS-CoV-2. The spike proteins (S protein) of SARS-CoV-2 perform a crucial function in viral infection establishment. ACE2 and TMPRSS2 play a pivotal role in viral entry. Upon viral entry, the released pro-inflammatory proteins (cytokines and chemokines) cause the migration of the T cells, monocytes, and macrophages to the infection site. IFNϒ released by T cells initiates a loop of pro-inflammatory feedback. The inflammatory state may further enhance with an increase in immune dysfunction responsible for the infection’s progression. A treatment approach that prevents ACE2-mediated viral entry and reduces inflammatory response is a crucial therapeutic intervention strategy, and nanomaterials and their conjugates are promising candidates. Nanoparticles can inhibit viral entry and replication. Nanomaterials have also found application in targeted drug delivery and also in developing a vaccine against SARS-CoV-2. Here, we briefly summarize the origin, transmission, and clinical features of SARS-CoV-2. We then discussed the immune response mechanisms of SARS-CoV-2. Finally, we further discussed nanotechnology’s potentials as an intervention strategy against SARS-CoV-2 infection. All these understandings will be crucial in developing therapeutic strategies against SARS-CoV-2.